8-K: Seer, Inc. Faces Nasdaq Non-Compliance on Audit Committee Composition; Annual Meeting Results Confirmed

Seer, Inc. announced it will no longer comply with Nasdaq's Audit Committee composition rule after its 2025 Annual Meeting but plans to utilize a cure period to regain compliance, while also confirming the election of directors and ratification of its independent auditor.

Summary

• Seer, Inc. notified The Nasdaq Stock Market LLC on July 7, 2025, that it will no longer be in compliance with Nasdaq Listing Rule 5605(c)(2)(A) following its 2025 Annual Meeting of Stockholders.
• The non-compliance specifically relates to the requirement for the Audit Committee to be composed of at least three members and for one member to possess specific financial sophistication (e.g., past employment in finance/accounting, professional certification, or senior financial oversight experience).
• The company intends to rely on the cure period provided by Nasdaq Listing Rule 5605(c)(4)(B) and is evaluating the appropriate membership and composition of its Board of Directors and Board committees to regain compliance.
• The 2025 Annual Meeting of Stockholders was held on July 7, 2025, with a quorum of 85,881,548 votes, representing approximately 90.16% of the 95,250,943 eligible votes.
• Stockholders elected all six director nominees: Omid Farokhzad, M.D., Meeta Gulyani, Terrance McGuire, Robert Langer, Sc.D., Dipchand (Deep) Nishar, and Nicolas Roelofs, Ph.D., to serve until the 2026 annual meeting.
• The appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified by stockholders with 85,859,701 votes in favor.

Sentiment

Score: 4

Explanation: The announcement of Nasdaq non-compliance is a negative development, indicating a governance issue. However, the company's stated intention to utilize the cure period and actively work towards regaining compliance, coupled with the successful completion of other annual meeting agenda items, mitigates the overall negative sentiment somewhat. It is not a catastrophic event but requires close monitoring.

Positives

• High stockholder participation at the Annual Meeting, with 90.16% of eligible votes constituting a quorum.
• All six director nominees were successfully elected to the Board, ensuring continuity of leadership.
• The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2025 was overwhelmingly ratified by stockholders.
• The company has a stated plan to address the Nasdaq non-compliance by utilizing the provided cure period and actively evaluating Board and committee composition.

Negatives

• Seer, Inc. will no longer be in compliance with Nasdaq Listing Rule 5605(c)(2)(A) regarding the composition of its Audit Committee after the 2025 Annual Meeting.
• The non-compliance specifically relates to the requirement for at least three Audit Committee members and one member having past employment experience in finance or accounting, requisite professional certification, or comparable financial sophistication.

Risks

• Risk of delisting from Nasdaq if the company fails to regain compliance with Listing Rule 5605(c)(2)(A) prior to the expiration of the applicable cure period.
• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those expressed or implied.

Future Outlook

The company intends to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) prior to the expiration of the applicable cure period granted under Nasdaq Listing Rule 5605(c)(4)(B).

Management Comments

• "The Company intends to rely on the cure period provided by the Nasdaq Listing Rule 5605(c)(4)(B)."
• "The Company is evaluating the appropriate membership and composition of its Board of Directors and Board committees and intends to regain compliance with the Nasdaq Listing Rule 5605(c)(2)(A) prior to the expiration of the applicable cure period."

Industry Context

This announcement primarily concerns corporate governance and compliance, which are fundamental requirements for all publicly traded companies. Non-compliance with exchange listing rules, regardless of industry, can impact investor confidence and market perception, potentially affecting a company's stock performance and access to capital markets.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact due to Nasdaq non-compliance and associated delisting risk, which could affect share price and liquidity. However, the company's stated plan to cure the issue and the successful election of directors and auditor ratification provide some stability.
• Management/Board: Increased focus and effort required to restructure the Audit Committee and regain Nasdaq compliance, potentially diverting resources.
• Regulatory Authorities: Nasdaq will monitor the company's progress in regaining compliance within the cure period.

Next Steps

• Seer, Inc. will evaluate the appropriate membership and composition of its Board of Directors and Board committees.
• The company intends to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) before the cure period expires.

Key Dates

Recommendation

Keywords

Seer Inc., SEER, Nasdaq, Audit Committee, Corporate Governance, SEC Filing, 8-K, Annual Meeting, Stockholder Vote, Compliance, Delisting Risk, Board of Directors, Deloitte & Touche LLP